Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Trientine (triethylenetetramine dihydrochloride) is a copper-chelating agent used to treat patients with Wilson's disease (WD). It has been considered safe, rarely causing neurological deterioration during initial treatment. We describe a patient diagnosed with WD who became neurologically disabled after treatment with trientine. On a fluid attenuated inversion recovery sequence, brain MRI showed increased areas of high signal intensity compared with initial brain MRI. The patient's neurological signs partially resolved after cessation of trientine treatment. Our findings suggest that treatment with trientine is associated with a risk of neurological deterioration in patients with WD. Copyright © 2012 Elsevier Ltd. All rights reserved.


Bomi Kim, Sun Ju Chung, Hae-Won Shin. Trientine-induced neurological deterioration in a patient with Wilson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2013 Apr;20(4):606-8

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 23274038

View Full Text